Picture of the Week and Clinical Case Presentations: 

  • To apply the principles of evidence-based medicine in the diagnosis and work-up of children with hematological and oncological diseases
  • To design and apply a treatment plan for patients with hematological and oncological diseases
  • To evaluate and manage the treatment and potential complications patients with complex hematological and oncological disorders experience

 

EBM: Neurofibromatosis Type 1 and MEK Inhibitors

  • Review the pathophysiology, manifestations, and diagnosis of neurofibromatosis type 1
  • Understand the long-term hematologic effects of MEK inhibitors use for NF1-associated plexiform neurofibromas
  • Understand how immune subset changes are associated with outcomes in patients receiving selumetinib for NF1-associated plexiform neurofibromas
Session date: 
03/26/2026 - 1:00pm to 2:00pm EDT
Location: 
Children's National Hospital
111 Michigan Avenue NW
Washington, DC 20010
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
    Children’s National Hospital designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    Children’s National Hospital will provide 1.00 Nursing Contact Hours for this Live activity.
  • 1.00 Participation
    Successful completion of this continuing education activity.
Please login or register to take this course.
Faculty List: 
Course Director(s)

Birte Wistinghausen, MD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Alan Siegel

has no relevant financial relationships to disclose at this time.